ESMO 2019

Showing 5 posts of 5 posts found.

opdivo_1_1

BMS’ Opdivo bests chemotherapy in oesophageal squamous cell carcinoma

October 2, 2019
Research and Development Bristol-Myers Squibb, Cancer, ESMO 2019, opdivo, pharma

Bristol-Myers Squibb took the opportunity at the European Society for Medical Oncology (ESMO) 2019 Annual Congress to present new Phase …

gsk_boronia_australia

GSK’s Zejula slows disease progression in a range of ovarian cancers

October 2, 2019
Research and Development Cancer, ESMO 2019, GSK, Zejula, ovarian cancer, pharma

At the 2019 European Society for Medical Oncology (ESMO) congress, GlaxoSmithKline unveiled new Phase 3 data on Zejula (niraparib) for …

Sanofi’s Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer

October 1, 2019
Manufacturing and Production, Research and Development ESMO 2019, Jevtana, Sanofi, pharma, prostate cancer

Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new …

roche__tree

Roche’s Tecentriq plus chemo shows promise in first-line, advanced bladder cancer

October 1, 2019
Manufacturing and Production, Research and Development Cancer, ESMO 2019, Roche, breast cancer, pharma, tecentriq

Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical …

astrazeneca_building_white

AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer

September 30, 2019
Research and Development, Sales and Marketing AstraZeneca, Cancer, ESMO 2019, Tagrisso, lung cancer, pharma

AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new …

Latest content